Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Christina Krupka"'
Autor:
Thomas Köhnke, Xilong Liu, Sascha Haubner, Veit Bücklein, Gerulf Hänel, Christina Krupka, Victor Solis-Mezarino, Franz Herzog, Marion Subklewe
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-13 (2022)
Abstract Background Immunotherapy of acute myeloid leukemia has experienced considerable advances, however novel target antigens continue to be sought after. To this end, unbiased approaches for surface protein detection are limited and integration w
Externí odkaz:
https://doaj.org/article/3deaa18de5b24156b55d8e2a8330a8ea
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-20 (2017)
Abstract The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the treatment of acute myeloid leukemi
Externí odkaz:
https://doaj.org/article/689bddaf940e40dc9633a5375c418ee6
Autor:
Todd A. Braciak, Claudia C. Roskopf, Sarah Wildenhain, Nadja C. Fenn, Christian B. Schiller, Ingo A. Schubert, Uwe Jacob, Annemarie Honegger, Christina Krupka, Marion Subklewe, Karsten Spiekermann, Karl-Peter Hopfner, Georg H. Fey, Michael Aigner, Stefan Krause, Andreas Mackensen, Fuat S. Oduncu
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological pro
Externí odkaz:
https://doaj.org/article/9c33b3300b544ab9bf536064eecde761
Autor:
Felix S. Lichtenegger, Maurine Rothe, Frauke M. Schnorfeil, Katrin Deiser, Christina Krupka, Christian Augsberger, Miriam Schlüter, Julia Neitz, Marion Subklewe
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Immune checkpoint inhibition has been shown to successfully reactivate endogenous T cell responses directed against tumor-associated antigens, resulting in significantly prolonged overall survival in patients with various tumor entities. For malignan
Externí odkaz:
https://doaj.org/article/e3b44104ed7d475bbd0fad0198a7ea17
Autor:
Binje Vick, Maja Rothenberg, Nadine Sandhöfer, Michela Carlet, Cornelia Finkenzeller, Christina Krupka, Michaela Grunert, Andreas Trumpp, Selim Corbacioglu, Martin Ebinger, Maya C André, Wolfgang Hiddemann, Stephanie Schneider, Marion Subklewe, Klaus H Metzeler, Karsten Spiekermann, Irmela Jeremias
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0120925 (2015)
Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease with poor outcome. Adequate model systems are required for preclinical studies to improve understanding of AML biology and to develop novel, rational treatment approac
Externí odkaz:
https://doaj.org/article/43a7a7aa98a74b85a84c42b3693bb303
Autor:
Marion Subklewe, Bettina Brauchle, Christina Krupka, Nadja C. Fenn, Ana Ogrinc Wagner, Felicitas Rataj, Katrin Deiser, Sebastian Kobold, Karsten Spiekermann, Monika Herrmann, Anetta Marcinek, Klaus H. Metzeler, Ralph Mocikat, Karl-Peter Hopfner
Publikováno v:
Blood. 132:2484-2494
The CD33-targeting bispecific T-cell engager (BiTE) AMG 330 proved to be highly efficient in mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet, T-cell activation is correlated with upregulation of programmed
Autor:
Mercedesz Balazs, Christina Krupka, Ryan Case, Dan A. Rock, Brendon Frank, Tara Arvedson, Sascha Haubner, Michael von Bergwelt-Baildon, Rebecca Goldstein, Michael C. Boyle, Christine Sastri, Priya Koppikar, Angela Coxon, Anja Henn, Bettina Brauchle, Klaus H. Metzeler, Tobias Raum, Christoph Dahlhoff, Joachim Wahl, Christine M. Karbowski, Veit Bücklein, Marion Subklewe, Matthias Friedrich, Karsten Spiekermann, Matthew J. Rardin, Chi-Ming Li
Publikováno v:
Molecular cancer therapeutics. 19(9)
Despite advances in the treatment of acute myeloid leukemia (AML), novel therapies are needed to induce deeper and more durable clinical response. Bispecific T-cell Engager (BiTE) molecules, which redirect patient T cells to lyse tumor cells, are a c
Autor:
Paul Kerbs, Philipp A. Greif, Wolfgang Hiddemann, Michel Sadelain, Marion Subklewe, Tobias Herold, Fabiana Perna, Samuel H. Berman, Stephanie Schneider, Sascha Haubner, Christina Krupka, Thomas Köhnke, Christian Augsberger, Felix S. Lichtenegger, X. Liu, Karsten Spiekermann, Christian Schmidt, Klaus H. Metzeler, Frauke M. Schnorfeil
Publikováno v:
Leukemia
Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-specific target antigens and clonal heterogeneity, leading to unwanted on-target off-leukemia toxicity and risk of relapse from minor clones. We hypothesize that
Autor:
To Uyen Do, Wolfgang Hiddemann, Arnima Bisht, Keith T. Wilson, Jon Terrett, Marion Subklewe, Veit Bücklein, Dee Aud, Jan Bögeholz, Christina Krupka, Felix S. Lichtenegger, Thomas Köhnke, Torben Altmann, Michael Roiss, Esteban Pombo-Villar, Christian Rohlff, Rachel L. Dusek
Publikováno v:
Oncotarget
Oncotarget 8, 35707-35717 (2017)
Oncotarget 8, 35707-35717 (2017)
// Christina Krupka 1, 2, 3 , Felix S. Lichtenegger 1, 2, 3 , Thomas Kohnke 1, 2, 3 , Jan Bogeholz 4 , Veit Bucklein 1, 2, 3 , Michael Roiss 1, 2, 3 , Torben Altmann 1, 2, 3 , To Uyen Do 5 , Rachel Dusek 5 , Keith Wilson 5, * , Arnima Bisht 5 , Jon T
Autor:
Kirsten Lauber, Marion Subklewe, Laia Pascual Ponce, Karl-Peter Hopfner, Nadine Moritz, Christina Krupka, Jan-Hendrik Kozik, Nadja C. Fenn
Publikováno v:
Oncotarget
Oncotarget 8, 11284-11301 (2017)
Oncotarget 8, 11284-11301 (2017)
// Laia Pascual Ponce 1, 5 , Nadja C. Fenn 1 , Nadine Moritz 1 , Christina Krupka 2, 3 , Jan-Hendrik Kozik 1 , Kirsten Lauber 4 , Marion Subklewe 2, 3 , Karl-Peter Hopfner 1, 5 1 Gene Center Munich, Department of Biochemistry, Ludwig-Maximilians-Univ